Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Inventory (2018 - 2025)

Coherus Oncology's Change in Inventory history spans 8 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Change in Inventory fell 82.74% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $17.1 million, down 46.46%, while the annual FY2025 figure was $17.1 million, 46.46% down from the prior year.
  • Change in Inventory for Q4 2025 was $1.1 million at Coherus Oncology, up from -$2.5 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $23.4 million in Q3 2022 and bottomed at -$7.5 million in Q2 2021.
  • The 5-year median for Change in Inventory is $8.1 million (2021), against an average of $7.5 million.
  • The largest annual shift saw Change in Inventory plummeted 241.08% in 2021 before it skyrocketed 443.63% in 2022.
  • A 5-year view of Change in Inventory shows it stood at $9.2 million in 2021, then increased by 6.56% to $9.8 million in 2022, then increased by 20.44% to $11.8 million in 2023, then crashed by 45.28% to $6.5 million in 2024, then crashed by 82.74% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Change in Inventory are $1.1 million (Q4 2025), -$2.5 million (Q3 2025), and -$3.8 million (Q2 2025).